Hongri Pharmaceuticals is a listed pharmaceutical company with a market value of more than 10 billion yuan, and the enterprise has developed into a high-tech pharmaceutical and health industry cluster spanning six major fields such as finished pharmaceutical products, traditional Chinese medicine granules, raw and auxiliary materials, medical devices, medical and healthcare services, and pharmaceutical and equipment intelligent supply chain, and integrating investment and financing, production, research and development, and sales.

As the eighth Red Sun Pharmaceutical Chinese medicine particles intelligent manufacturing base, this settled in Shanghe Red Sun Pharmaceutical Chinese medicine formula particles intelligent manufacturing project, plans a total investment of 750 million yuan, covering a total area of 100 acres, the project is expected to be put into operation after the annual extraction of units of 10,000 tons of traditional Chinese medicinal herbs. In the production chain to build and management mode, the base will make full use of the industrial advantages and technical advantages of Hongri Pharmaceuticals, with the help of cutting-edge AI, 5G, cloud, big data and other advanced technologies, through a series of digital means, to achieve the production of the whole process of management and monitoring, to create the industry's optimal intelligent production line, to provide the traditional Chinese medicine industry from "Made in China" to "Made in China", and to provide the Chinese medicine industry from "Made in China" to "Made in China". This will set a new model for the transformation and upgrading of the traditional Chinese medicine industry from "Made in China" to "Made in China".